Literature DB >> 10366642

Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery.

G Hatzidimitriou1, U D McCann, G A Ricaurte.   

Abstract

The recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") is a potent and selective brain serotonin (5-HT) neurotoxin in animals and, possibly, in humans. The purpose of the present study was to determine whether brain 5-HT deficits persist in squirrel monkeys beyond the 18-month period studied previously and to identify factors that influence recovery of injured 5-HT axons. Seven years after treatment, abnormal brain 5-HT innervation patterns were still evident in MDMA-treated monkeys, although 5-HT deficits in some regions were less severe than those observed at 18 months. No loss of 5-HT nerve cell bodies in the rostral raphe nuclei was found, indicating that abnormal innervation patterns in MDMA-treated monkeys are not the result of loss of a particular 5-HT nerve cell group. Factors that influence recovery of 5-HT axons after MDMA injury are (1) the distance of the affected axon terminal field from the rostral raphe nuclei, (2) the degree of initial 5-HT axonal injury, and possibly (3) the proximity of damaged 5-HT axons to myelinated fiber tracts. Additional studies are needed to better understand these and other factors that influence the response of primate 5-HT neurons to MDMA injury and to determine whether the present findings generalize to humans who use MDMA for recreational purposes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10366642      PMCID: PMC6782677     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  40 in total

1.  Long-term effects of chronic methamphetamine administration in rhesus monkeys.

Authors:  W L Woolverton; G A Ricaurte; L S Forno; L S Seiden
Journal:  Brain Res       Date:  1989-05-01       Impact factor: 3.252

2.  Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey.

Authors:  B Lavoie; A Parent
Journal:  J Comp Neurol       Date:  1990-09-01       Impact factor: 3.215

Review 3.  The primate serotonergic system: a review of human and animal studies and a report on Macaca fascicularis.

Authors:  E C Azmitia; P J Gannon
Journal:  Adv Neurol       Date:  1986

4.  The ultrastructural localization of serotonin immunoreactivity in myelinated and unmyelinated axons within the medial forebrain bundle of rat and monkey.

Authors:  E Azmitia; P Gannon
Journal:  J Neurosci       Date:  1983-10       Impact factor: 6.167

5.  Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine.

Authors:  M A Wilson; G A Ricaurte; M E Molliver
Journal:  Neuroscience       Date:  1989       Impact factor: 3.590

6.  Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity.

Authors:  E O'Hearn; G Battaglia; E B De Souza; M J Kuhar; M E Molliver
Journal:  J Neurosci       Date:  1988-08       Impact factor: 6.167

7.  Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA).

Authors:  W Slikker; S F Ali; A C Scallet; C H Frith; G D Newport; J R Bailey
Journal:  Toxicol Appl Pharmacol       Date:  1988-07       Impact factor: 4.219

8.  Ultrastructural organization of regenerated serotonin axons in the dorsomedial hypothalamus of the adult rat.

Authors:  M Frankfurt; A Beaudet
Journal:  J Neurocytol       Date:  1987-12

9.  Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part II: Radioligand binding and autoradiography studies.

Authors:  R Lew; K E Sabol; C Chou; G L Vosmer; J Richards; L S Seiden
Journal:  J Pharmacol Exp Ther       Date:  1996-02       Impact factor: 4.030

10.  Dual serotoninergic projections to forebrain in the rat: morphologically distinct 5-HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives.

Authors:  L A Mamounas; C A Mullen; E O'Hearn; M E Molliver
Journal:  J Comp Neurol       Date:  1991-12-15       Impact factor: 3.215

View more
  78 in total

1.  Investigation of the mechanisms mediating MDMA "Ecstasy"-induced increases in cerebro-cortical perfusion determined by btASL MRI.

Authors:  J Rouine; M E Kelly; C Jennings-Murphy; P Duffy; I Gorman; S Gormley; C M Kerskens; Andrew Harkin
Journal:  Psychopharmacology (Berl)       Date:  2014-11-01       Impact factor: 4.530

2.  The "ecstasy" hangover: hyponatremia due to 3,4-methylenedioxymethamphetamine.

Authors:  Stephen J Traub; Robert S Hoffman; Lewis S Nelson
Journal:  J Urban Health       Date:  2002-12       Impact factor: 3.671

3.  Evidence for chronically altered serotonin function in the cerebral cortex of female 3,4-methylenedioxymethamphetamine polydrug users.

Authors:  Christina R Di Iorio; Tristan J Watkins; Mary S Dietrich; Aize Cao; Jennifer U Blackford; Baxter Rogers; Mohammed S Ansari; Ronald M Baldwin; Rui Li; Robert M Kessler; Ronald M Salomon; Margaret Benningfield; Ronald L Cowan
Journal:  Arch Gen Psychiatry       Date:  2011-12-05

4.  Prospective memory deficits in Ecstasy users: effects of longer ongoing task delay interval.

Authors:  Michael Weinborn; Steven Paul Woods; Claire Nulsen; Katherine Park
Journal:  J Clin Exp Neuropsychol       Date:  2011-11-03       Impact factor: 2.475

5.  Reduced 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-initiated oxidative DNA damage and neurodegeneration in prostaglandin H synthase-1 knockout mice.

Authors:  Winnie Jeng; Peter G Wells
Journal:  ACS Chem Neurosci       Date:  2010-02-23       Impact factor: 4.418

6.  The Netherlands XTC Toxicity (NeXT) study: objectives and methods of a study investigating causality, course, and clinical relevance.

Authors:  Maartje M L De Win; Gerry Jager; Hylke K E Vervaeke; Thelma Schilt; Liesbeth Reneman; Jan Booij; Frank C Verhulst; Gerard J Den Heeten; Nick F Ramsey; Dirk J Korf; Wim Van den Brink
Journal:  Int J Methods Psychiatr Res       Date:  2005       Impact factor: 4.035

7.  Occipital cortical proton MRS at 4 Tesla in human moderate MDMA polydrug users.

Authors:  Ronald L Cowan; Nicolas R Bolo; Mary Dietrich; Erica Haga; Scott E Lukas; Perry F Renshaw
Journal:  Psychiatry Res       Date:  2007-06-18       Impact factor: 3.222

Review 8.  Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.

Authors:  M Isabel Colado; Esther O'Shea; A Richard Green
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

9.  Anxiety, depression, and behavioral symptoms of executive dysfunction in ecstasy users: contributions of polydrug use.

Authors:  Krista Lisdahl Medina; Paula K Shear
Journal:  Drug Alcohol Depend       Date:  2006-10-30       Impact factor: 4.492

10.  Sleep apnea in young abstinent recreational MDMA ("ecstasy") consumers.

Authors:  Una D McCann; Francis P Sgambati; Alan R Schwartz; George A Ricaurte
Journal:  Neurology       Date:  2009-12-02       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.